Immunoplacental therapy, a potential multi-epitope cancer vaccine
Immunoplacental therapy, a potential multi-epitope cancer vaccine
复制标题
DOI：
10.1016/j.mehy.2005.12.011
复制
发表时间：
2006-01-01
影响因子：
4.7
通讯作者：
Harandi, A
中科院分区：
文献类型：
--
作者：
Harandi, A
近年来，肿瘤免疫学领域取得了长足的进步。回顾分析以前的疫苗策略，结合目前的知识，可能会为这种治疗方式提供更多的洞察力。本文综述了免疫胎盘疗法(IPT)，这是一种癌症疫苗，由活体足月分娩后从人胎盘中提取的绒毛组成。这种疗法最早是在20世纪70年代由Valentin 1.Govallo医学博士引入的，他注意到了怀孕和癌症之间的免疫学相似性。根据Govatto的说法，癌症免疫治疗的目标是将同种异体胎儿移植视为一种“浸润性肿瘤”，并在肿瘤患者中创造一种类似于孕妇自然流产的免疫状态。胎盘与癌细胞具有相同的生长机制、抗原决定因素和免疫逃逸特性；这包括许多肿瘤相关抗原、血管生成生长因子、补体调节蛋白和有助于其生存的缺陷的凋亡机制。胎盘疫苗可以起到多表位疫苗的作用；人体识别这种疫苗的胎盘抗原是外来的，从而刺激针对癌症肿瘤相关抗原以及有助于癌症血管生成、补体调节和抗凋亡的蛋白质的交叉反应的体液和细胞免疫反应。随着分子和细胞癌症免疫学的最新进展，Govalto介绍的模型可能为癌症免疫治疗提供一种重要的战略途径。(C)2005爱思唯尔有限公司。保留所有权利。
The field of tumor immunology has made great advancements in recent years. A retrospective analysis of previous vaccine strategies combined with present knowledge may provide additional insight in this treatment modality. This article provides a review of immunoplacental therapy (IPT), a cancer vaccine consisting of chorionic villi extractions from the human placenta after a live full-term delivery. This therapy was first introduced in the 1970s by Valentin 1. Govallo, M.D., Ph.D., who noted the immunological similarities between pregnancy and cancer. The goal of cancer immunotherapy, according to Govatto, is to view the fetal allograft as an "impregnating tumor" and create an immunological state in the oncological patient analogous to a spontaneous abortion in a pregnant women. The placenta shares identical growth mechanisms, antigenic determinants, and immune-escape properties with cancer cells; this includes numerous tumor-associated antigens, angiogenic growth factors, complement regulatory proteins, and defective apoptotic mechanisms which aid in their survival. Placental vaccination may function as a multi-epitope vaccine; the body recognizes the placental antigens of this vaccine as foreign, and thus stimulates a cross reactive humoral and cell-mediated immune response targeting cancer tumor-associated antigens as well as proteins that aid in cancer angiogenesis, complement regulation, and apoptotic resistance. With recent advancements in molecular and cellular cancer immunology, the model introduced by Govalto may provide an important strategic approach to cancer immunotherapy. (c) 2005 Elsevier Ltd. All rights reserved.